Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Analysis finds significant variations in national COVID-19 treatment recommendations

National clinical guidelines for the treatment of COVID-19 vary significantly around the world, with under-resourced countries the most likely to diverge from gold standard (World Health Organization; WHO) treatment recommendations, finds a comparative analysis published in the open access journal BMJ Global Health.

23 Apr 2024

Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial

A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.

8 Apr 2024

Molnupiravir influences SARS-CoV-2 evolution in immunocompromised patients

Study found that the antiviral molnupiravir affects the evolution of SARS-CoV-2 in immunocompromised patients, suggesting its use modifies viral mutation patterns and may impact viral evolution.

25 Mar 2024

New drug candidate designed at the atomic level could help halt emerging SARS-CoV-2 variants

Although COVID-19 has faded from the headlines, SARS-CoV-2 – the coronavirus behind the pandemic – is still rampantly infecting people around the world.

14 Mar 2024

Study shows ritonavir-boosted nirmatrelvir remains effective against new omicron variants in the U.S

The effectiveness of ritonavir-boosted nirmatrelvir (NMV-r) against Omicron variants.

13 Feb 2024

Paxlovid enhances treatment options for COVID-19 patients

The design, synthesis, and mechanism of action of Paxlovid.

6 Feb 2024

Paxlovid treatment in 20% of COVID-19 patients could avert 850,000 hospitalizations, save up to $170 billion

A study in the Emerging Infectious Diseases journal shows treating 20% of COVID-19 patients with Paxlovid could save up to 0.85 million lives and reduce the economic burden by US $170.17 billion in the US.

14 Jan 2024

Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals

Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.

8 Jan 2024

Paxlovid does not reduce long COVID risk in vaccinated individuals, study finds

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.

4 Jan 2024

Exploring the global health challenge of hepatitis D

Review explores the global impact of the hepatitis D virus (HDV) on public health, detailing its transmission, clinical course, diagnosis, and treatment options.

2 Jan 2024

Research shows how HIV drug could stop many coronavirus diseases

Coronaviruses are a global public health risk, with three highly infectious species, including SARS-CoV-2, emerging in the last 20 years.

5 Dec 2023

Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity

Review examines nirmatrelvir and bisphosphonates in treating COVID-19, revealing their impact on SARS-CoV-2-specific adaptive immunity and potential to mitigate severe infections, highlighting the need for balanced long-term immunity management.

16 Nov 2023

One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals

The frequency of viral rebound (VR) among acute coronavirus disease 2019 patients.

16 Nov 2023

Study observes virologic rebound in 20% of COVID-19 patients treated with nirmatrelvir-ritonavir

An observational study of patients being treated for acute COVID-19 in a multicenter health care system observed virologic rebound in about 20 percent of patients treated with nirmatrelvir-ritonavir (N-R) versus about 2 percent of those who did not receive treatment. The findings are published in Annals of Internal Medicine.

13 Nov 2023

One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test-;a phenomenon known as virologic rebound.

13 Nov 2023

WHO experts update guidance on COVID-19 treatments

A panel of international experts representing the World Health Organization's Guideline Development Group has updated its guidance on treatments for patients with covid-19.

9 Nov 2023

Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited.

24 Oct 2023

Paxlovid treatment provides protection against COVID-19 for both mother and child

A new mouse model of infection with the COVID-19-causing SARS-CoV-2 virus during pregnancy tracks closely the disease course doctors have observed in SARS-CoV-2-infected pregnant patients, and suggests that treatment with the antiviral Paxlovid provides protection for both mother and child.

16 Oct 2023

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment's efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.

8 Oct 2023

NIH launches and opens enrollment for phase 2 clinical trials to evaluate long COVID treatments

Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months.

31 Jul 2023